We are thrilled to announce that EV艑Q Nano, a pioneering nanoscience company renowned for engineering innovative nanoparticles, has successfully raised $18,000,000 in its latest funding round. This remarkable injection of capital reflects strong investor confidence in EV艑Q Nano鈥檚 multi-patented, high-volume laser nanofabrication process鈥攁 groundbreaking method that produces uniform, sub-10 nm particles with distinct surface chemistries. This technological edge not only distinguishes EV艑Q Nano in the rapidly evolving world of nanoscience but also positions the company to significantly influence the life sciences, materials, and textile industries.
The new funds will be strategically channelled into advancing products across the company鈥檚 three core sectors. EV艑Q Bio continues to make headway with its inhaled therapeutic based on EVQ-218, a promising treatment for pulmonary bacterial infections in cystic fibrosis patients. With a successful pre-Investigational New Drug meeting with the U.S. Food and Drug Administration under its belt, EV艑Q Bio is confidently progressing toward Phase I clinical trials. Meanwhile, EV艑Q MedTech is enhancing medical devices with antimicrobial properties aimed at reducing healthcare-associated infections (HAIs), thereby potentially benefiting over one million hospital patients annually through partnerships with leading catheter manufacturers. Additionally, FUZE Technologies is expanding its footprint in the textile, hospitality, fitness, and workspace sectors with EPA-approved antimicrobial solutions that are free from chemicals, toxicity, and environmental waste鈥攃ollaborating with top global brands such as Nike, Adidas, and Marriott, among others.
This funding milestone not only underscores the innovative spirit at the heart of EV艑Q Nano but also accelerates its mission to revolutionize healthcare, technology, and industrial applications with cutting-edge nanoscience solutions.
